Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Pandemic Hurt, But EY Expects More Biopharma Deal-Making In 2021

Life Sciences M&A Was Almost Half Of 2019’s Record

Executive Summary

COVID-19 drove down both deal-making and biopharma “firepower” for part of 2020, but the industry began rebounding. This year should see significant bolt-on M&A activity and technology-driven alliances, according to EY.

You may also be interested in...



Deals Or No Deals, J.P. Morgan Sets The Tone For 2022

No big buyouts were revealed during the annual J.P. Morgan Healthcare Conference for a third year in a row. Big pharma firms are in acquisition mode, but execs stress desire for easy integrations and scientific alliances. 

EY: Don’t Expect Mega-Mergers To Return, But ‘Never Say Never’

Firm’s annual biopharma firepower report notes there were no mega-mergers in 2021 and the conditions continue to make smaller deals and partnerships a better risk proposition.

How The Pandemic Changed Deal-Making Between Biotechs And Big Pharma

Speakers on a panel about health care deal-making discussed the influx of capital into biotech during the past two years, how that has impacted deal-making and whether those changes will last.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel